Merck Nabs Partial Win In Vioxx Securities Fraud Row
By Zachary Zagger · May 13, 2015, 8:02 PM EDT
A New Jersey federal judge ruled Wednesday that a class alleging securities fraud could not prove Merck & Co. Inc. misrepresented Vioxx's heart attack risks at least prior to a study...
To view the full article, register now.